Event Type
Disclosure
Voluntary
Variant
8-K
, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
Other Events. On October 9, 2025, at the 32nd Annual European Society of Gene and Cell Therapy Congress, the Company reported in vivo preclinical proof-of-conce
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on October 9, 2025* 104 Cover Page Interactive